公开(公告)号：US07438907B2

公开(公告)日：2008-10-21

申请号：US10714353

申请日：2003-11-14

Applicant: Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G. J. Van De Winkel ,  Denise Leah Williams ,  Jørgen Petersen ,  Ole Baadsgaard

Inventor： Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G. J. Van De Winkel ,  Denise Leah Williams ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/00

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20240409656A1

公开(公告)日：2024-12-12

申请号：US18664772

申请日：2024-05-15

Applicant: GENMAB A/S

Inventor： Nurgul KILAVUZ ,  Mariana SACCHI

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to improved methods for reducing cytokine release syndrome following interruption of the epcoritamab dosing schedule for the treatment of CD20 B-cell expressing cancers.

公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240254252A1

公开(公告)日：2024-08-01

申请号：US17259342

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart E. C. G. DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.

公开(公告)号：US20240228641A9

公开(公告)日：2024-07-11

申请号：US18478711

申请日：2023-09-29

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20240150484A1

公开(公告)日：2024-05-09

申请号：US18281372

申请日：2022-03-11

Applicant: GENMAB A/S

Inventor： Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran F. LABRIJN

IPC: C07K16/28 ,  C07K1/107 ,  C07K16/18 ,  C07K16/32

CPC classification number: C07K16/2887 ,  C07K1/1075 ,  C07K16/18 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/92 ,  C07K2317/94

Abstract: Described herein are proteins comprising an Fc region or the like, such as monoclonal, bispecific and multispecific antibodies, wherein the Fc region has been modified to eliminate or strongly reduce Fc-mediated effector functions, while at the same time allow for good developability, for therapeutic purposes and where such effector functions are undesired.

公开(公告)号：US20240132607A1

公开(公告)日：2024-04-25

申请号：US18478711

申请日：2023-09-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20230416403A1

公开(公告)日：2023-12-28

申请号：US18062473

申请日：2022-12-06

Applicant: Genmab A/S

Inventor： Sandra VERPLOEGEN ,  David P. E. SATIJN ,  Rene M. A. HOET ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Vibeke Miller BREINHOLT ,  Eva EHRNROOTH ,  Ole BAADSGAARD ,  Tom VINK ,  Willem Karel BLEEKER ,  Mischa HOUTKAMP ,  Maroeska OUDSHOORN ,  Rob N. DE JONG

IPC: C07K16/36 ,  A61K39/395

CPC classification number: C07K16/36 ,  A61K39/395 ,  C07K2317/565 ,  A61K2039/505

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US11795214B2

公开(公告)日：2023-10-24

申请号：US16399424

申请日：2019-04-30

Applicant: GENMAB A/S

Inventor： Paul Parren ,  Patrick Van Berkel ,  Ewald Van Den Bremer

IPC: C07K16/18 ,  C07K16/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K16/18 ,  C07K16/00 ,  G01N33/5014 ,  G01N33/6854 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/734

Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.